Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (14)

2023

  1. An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas

    Cancers, Vol. 15, Núm. 14

  2. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY

    Journal of Endocrinological Investigation, Vol. 46, Núm. 4, pp. 805-814

  3. Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

    Neuroendocrinology, Vol. 113, Núm. 6, pp. 657-666

  4. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas

    Frontiers in Endocrinology, Vol. 14

  5. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas

    Endocrine-related cancer, Vol. 29, Núm. 12, pp. 645-655

  2. Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours

    Scientific reports, Vol. 12, Núm. 1, pp. 2671

2020

  1. SEEN guidelines for the management and prevention of acute adrenal insufficiency

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 1, pp. 53-60

2019

  1. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329

2016

  1. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

2015

  1. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

    European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122

2013

  1. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues

    European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13

2010

  1. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2009

  1. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy

    European Journal of Endocrinology, Vol. 160, Núm. 4, pp. 535-542